Nemes Rush Group LLC Bio Line Rx Ltd. Transaction History
Nemes Rush Group LLC
- $809 Billion
- Q4 2024
A detailed history of Nemes Rush Group LLC transactions in Bio Line Rx Ltd. stock. As of the latest transaction made, Nemes Rush Group LLC holds 12,000 shares of BLRX stock, worth $45,360. This represents 0.0% of its overall portfolio holdings.
Number of Shares
12,000
Previous 12,000
-0.0%
Holding current value
$45,360
Previous $13.4 Million
80.89%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding BLRX
# of Institutions
37Shares Held
2.98MCall Options Held
75.1KPut Options Held
5.1K-
Highbridge Capital Management LLC New York, NY1.01MShares$3.82 Million0.05% of portfolio
-
Cvi Holdings, LLC Wilmington, DE816KShares$3.08 Million4.05% of portfolio
-
Values First Advisors, Inc.166KShares$629,1770.02% of portfolio
-
Pvg Asset Management Corp Golden, CO157KShares$594,2720.37% of portfolio
-
Atria Wealth Solutions, Inc. New York, NY94.1KShares$355,8220.0% of portfolio
About BioLineRx Ltd.
- Ticker BLRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 61,524,500
- Market Cap $233M
- Description
- BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials ...